ID2 Expression in Non-Small Cell Lung Cancer
Author Information
Author(s): Rollin Jérôme, Bléchet Claire, Régina Sandra, Tenenhaus Arthur, Guyétant Serge, Gidrol Xavier
Primary Institution: CEA, DSV, IRCM, Laboratoire d'Exploration Fonctionnelle des Génomes, Evry, France
Hypothesis
The expression of ID2 in non-small cell lung cancer (NSCLC) patients is related to their clinicopathological features and prognosis.
Conclusion
High nuclear expression of ID2 is an independent and unfavorable prognostic factor for survival in patients with poorly differentiated NSCLC.
Supporting Evidence
- ID2 expression was detected in both nuclear and cytoplasmic compartments in NSCLC tumors.
- High nuclear expression of ID2 was found to be inversely correlated with tumor differentiation grade.
- Patients with poorly differentiated tumors and high nuclear ID2 expression had a significantly shorter overall survival.
Takeaway
This study found that a protein called ID2 can help predict how well patients with a certain type of lung cancer will do, especially if their tumors are not well differentiated.
Methodology
Immunohistochemistry was performed on tissue microarrays containing 62 NSCLC tumors to evaluate ID2 expression.
Limitations
The study's findings may not be generalizable due to the specific patient population and the focus on poorly differentiated tumors.
Participant Demographics
{"total":62,"sex":{"female":8,"male":54},"smoking_status":{"non_smokers":5,"smokers":57},"histological_type":{"adenocarcinoma":33,"squamous_cell_carcinoma":19,"other":10},"differentiation_grade":{"well":17,"moderately":26,"poorly":19}}
Statistical Information
P-Value
p=0.036
Confidence Interval
95% CI = 1.2–161
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website